UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 843

Sortiert nach

Natural Killer Cell Education and Tolerance

Cell, 2010-09, Vol.142 (6), p.847-856

2010

Volltextzugriff (PDF)

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

PloS one, 2021-03, Vol.16 (3), p.e0247990-e0247990

2021

Volltextzugriff (PDF)

CD94 Is Essential for NK Cell-Mediated Resistance to a Lethal Viral Disease

Immunity (Cambridge, Mass.), 2011-04, Vol.34 (4), p.579-589

2011

Volltextzugriff (PDF)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction

PloS one, 2016, Vol.11 (1), p.e0146372-e0146372

2016

Volltextzugriff (PDF)

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93

PloS one, 2014-01, Vol.9 (1), p.e83884-e83884

2014

Volltextzugriff (PDF)

Key roles of adjuvants in modern vaccines

Nature medicine, 2013-12, Vol.19 (12), p.1597-1608

2013

Volltextzugriff (PDF)

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy

Vaccine, 2015-11, Vol.33 (48), p.6570-6578

2015

Volltextzugriff (PDF)

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions

npj vaccines, 2023-02, Vol.8 (1), p.14-14, Article 14

2023

Volltextzugriff (PDF)

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy

Frontiers in immunology, 2021-06, Vol.12, p.683157-683157

2021

Volltextzugriff (PDF)

Formulated Phospholipids as Non-Canonical TLR4 Agonists

Pharmaceutics, 2022-11, Vol.14 (12), p.2557

2022

Volltextzugriff (PDF)

Development and function of CD94-deficient natural killer cells

PloS one, 2010-12, Vol.5 (12), p.e15184-e15184

2010

Volltextzugriff (PDF)

Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection

The Journal of experimental medicine, 2009-04, Vol.206 (4), p.807-817

2009

Volltextzugriff (PDF)

Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC

Blood, 2011-06, Vol.117 (26), p.7032-7041

2011

Volltextzugriff (PDF)

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine

Heliyon, 2023-06, Vol.9 (6), p.e17325-e17325, Article e17325

2023

Volltextzugriff (PDF)

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection

Nature immunology, 2010-04, Vol.11 (4), p.321

2010

Volltextzugriff (PDF)

Enhanced Anti- Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment

Vaccines (Basel), 2018-05, Vol.6 (2), p.30

2018

Volltextzugriff (PDF)

The science of vaccine adjuvants: advances in TLR4 ligand adjuvants

Current opinion in immunology, 2016-08, Vol.41, p.85-90

2016

Volltextzugriff (PDF)

Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses

The Journal of immunology (1950), 2018-07, Vol.201 (1), p.98-112

2018

Volltextzugriff (PDF)

Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus

Proceedings of the National Academy of Sciences - PNAS, 2010-09, Vol.107 (36), p.15844-15849

2010

Volltextzugriff (PDF)

Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells

Nanoscale, 2020-01, Vol.12 (4), p.2515-2523

2020

Volltextzugriff (PDF)

αv Integrins regulate germinal center B cell responses through noncanonical autophagy

The Journal of clinical investigation, 2018-08, Vol.128 (9), p.4163-4178

2018

Volltextzugriff (PDF)

Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment

The Journal of infectious diseases, 2013-04, Vol.207 (8), p.1242-1252

2013

Volltextzugriff (PDF)

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

Journal of controlled release, 2013-11, Vol.172 (1), p.190-200

2013

Volltextzugriff (PDF)

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

Journal of controlled release, 2016-12, Vol.244 (Pt A), p.98-107

2016

Volltextzugriff (PDF)

1 – 25 von 843

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(757)
Mit Volltextzugriff
(768)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Natural Killer Cell Education and Tolerance

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

CD94 Is Essential for NK Cell-Mediated Resistance to a Lethal Viral Disease

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93

Key roles of adjuvants in modern vaccines

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy

Formulated Phospholipids as Non-Canonical TLR4 Agonists

Development and function of CD94-deficient natural killer cells

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET ® CC-96191

Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection

Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection

Enhanced Anti- Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment

The science of vaccine adjuvants: advances in TLR4 ligand adjuvants

Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses

Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus

Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells

αv Integrins regulate germinal center B cell responses through noncanonical autophagy

Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

Suchergebnisse filtern